TABLE 1.

Demographic table displaying individual data for each patient

Screening no.	Sex	Age (yr)	Body wt (kg)	BMI (kg/m2)	Infectiona	Pathogenb	Survival (daysc)	Dose (mg/kg)d
1	M	74	89	27.47	Endocarditis of the aortic and mitral valves; aspiration pneumonia	Enterococcus faecalis	16	11.24
2	M	65	77	26.03	Acute pancreatitis and peritonitis	VRE	Alive	12.99
3	M	76	90	27.78	ARDS		Alive	11.11
4	M	65	98	25.25	Septic shock		9	10.20
5	M	79	75	24.49	Postoperative sepsis following bio-AVR		Alive	13.33
6	M	72	160	52.24	Infected hemorrhage of the psoas muscle; putrid bronchial secretion		158	6.25
7	F	55	70	24.22	Streptococcus pneumoniae sepsis after splenectomy	S. pneumoniae	Alive	14.29
8	M	73	85	24.84	Pancreatitis, tuberculosis		85	11.76
9	M	65	100	30.86	E. coli sepsis following SBP	Escherichia coli	12	10.00
10	M	77	60	19.37	S. pneumoniae sepsis	S. pneumoniae	12	16.67
11	M	42	120	37.04	Pneumonia		13	8.33
13	M	62	102	32.93	Endocarditis of the aortic valve	Staphylococcus aureus	6	9.80
14	M	56	75	23.15	Septic shock, pleural empyema	E. coli	5	13.33
Mean ± SD		66.9 ± 10.2	92.4 ± 24.8	28.9 ± 8.0				11.5 ± 2.6

^aARDS, adult respiratory distress syndrome; bio-AVR, aortic valve replacement with a bioprosthetic valve; SBP, spontaneous bacterial peritonitis.

^bVRE, vancomycin-resistant enterococcus.

^cDays after inclusion in the trial.

^dEach patient received a doripenem dose of 1,000 mg q8h.